The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 05, 2023

Filed:

Mar. 05, 2021
Applicant:

Beta Bionics, Inc., Concord, MA (US);

Inventors:

Edward R. Damiano, Acton, MA (US);

Firas H. El-Khatib, Allston, MA (US);

Assignee:

BETA BIONICS, INC., Concord, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61M 5/172 (2006.01); G16H 20/17 (2018.01); G16H 10/40 (2018.01); G16H 40/67 (2018.01); A61M 5/142 (2006.01); G16H 20/60 (2018.01);
U.S. Cl.
CPC ...
A61M 5/1723 (2013.01); A61M 5/14244 (2013.01); G16H 10/40 (2018.01); G16H 20/17 (2018.01); G16H 20/60 (2018.01); G16H 40/67 (2018.01); A61M 2005/14208 (2013.01); A61M 2005/1726 (2013.01); A61M 2205/16 (2013.01); A61M 2205/3553 (2013.01); A61M 2205/3561 (2013.01); A61M 2205/3584 (2013.01); A61M 2205/3592 (2013.01); A61M 2205/50 (2013.01); A61M 2205/502 (2013.01); A61M 2205/505 (2013.01); A61M 2205/52 (2013.01); A61M 2230/201 (2013.01);
Abstract

A blood glucose control system is configured to modify therapy provide to a subject and determine whether the modified therapy results in a statistically significant improvement in glycemic control. The system obtains glycemic control information resulting from delivery of first therapy using a first value of a control parameter and determines a first effect corresponding to the first therapy. The control parameter is set to a second value that differs from the first value. The system obtains glycemic control information resulting from the delivery of the second therapy using the second value of the control parameter and determines a second effect corresponding to the second therapy. The system can perform a comparative assessment and determine whether the second value for the control parameter results in a statistically significant improvement in glycemic control for the subject.


Find Patent Forward Citations

Loading…